ALNY vs RELIW · P/E 76, rev $1.29B vs rev $14.1M
Alnylam Pharmaceuticals Inc (ALNY) versus Reliance Global Group Inc (RELIW) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Reliance Global Group Inc (RELIW) common stock listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported RELIW revenue for 2024-12-31 was $14.1M. Net income was -$9.1M. Revenue was up 2.3% from 2023-12-31 to 2024-12-31. RELIW currently screens at market cap $39.2M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. RELIW currently screens at market cap $39.2M.
Not investment advice. Open the ALNY and RELIW stock pages for the full models.
Not investment advice.